TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

EDARBYCLOR

AZILSARTAN KAMEDOXOMIL
Cardiovascular Approved 2011-12-20
1
Indication
--
Phase 3 Trials
14
Years on Market

Details

Status
Prescription
First Approved
2011-12-20
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: AZILSARTAN KAMEDOXOMIL , CHLORTHALIDONE

EDARBYCLOR Approval History

Loading approval history...

What EDARBYCLOR Treats

2 indications

EDARBYCLOR is approved for 2 conditions since its original approval in 2011. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypertension
  • Myocardial Infarction
Source: FDA Label

EDARBYCLOR Boxed Warning

FETAL TOXICITY When pregnancy is detected, discontinue Edarbyclor as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue EDARBYCLOR as soon as possib...

Drugs Similar to EDARBYCLOR

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ALISKIREN HEMIFUMARATE
ALISKIREN HEMIFUMARATE
2 shared
PH HEALTH
Shared indications:
HypertensionMyocardial Infarction
ATENOLOL
ATENOLOL
2 shared
AIPING PHARM INC
Shared indications:
HypertensionMyocardial Infarction
ATENOLOL AND CHLORTHALIDONE
ATENOLOL
2 shared
WATSON LABS
Shared indications:
HypertensionMyocardial Infarction
AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE
AZILSARTAN KAMEDOXOMIL
2 shared
ALKEM LABS LTD
Shared indications:
HypertensionMyocardial Infarction
AZOR
AMLODIPINE BESYLATE
2 shared
COSETTE
Shared indications:
HypertensionMyocardial Infarction
BYSTOLIC
NEBIVOLOL HYDROCHLORIDE
2 shared
AbbVie
Shared indications:
HypertensionMyocardial Infarction
CADUET
AMLODIPINE BESYLATE
2 shared
PHARMACIA
Shared indications:
HypertensionMyocardial Infarction
CARVEDILOL PHOSPHATE
CARVEDILOL PHOSPHATE
2 shared
Sun Pharma
Shared indications:
Myocardial InfarctionHypertension
COREG
CARVEDILOL
2 shared
WAYLIS THERAP
Shared indications:
Myocardial InfarctionHypertension
COREG CR
CARVEDILOL PHOSPHATE
2 shared
WAYLIS THERAP
Shared indications:
Myocardial InfarctionHypertension
DIOVAN
VALSARTAN
2 shared
Novartis
Shared indications:
HypertensionMyocardial Infarction
DIOVAN HCT
HYDROCHLOROTHIAZIDE
2 shared
Novartis
Shared indications:
HypertensionMyocardial Infarction
EXFORGE
AMLODIPINE BESYLATE
2 shared
Novartis
Shared indications:
HypertensionMyocardial Infarction
EXFORGE HCT
AMLODIPINE BESYLATE
2 shared
Novartis
Shared indications:
HypertensionMyocardial Infarction
INNOPRAN XL
PROPRANOLOL HYDROCHLORIDE
2 shared
ANI PHARMS
Shared indications:
HypertensionMyocardial Infarction
JAVADIN
CLONIDINE HYDROCHLORIDE
2 shared
AZURITY
Shared indications:
HypertensionMyocardial Infarction
LISINOPRIL
LISINOPRIL
2 shared
Aurobindo Pharma
Shared indications:
HypertensionMyocardial Infarction
LISINOPRIL AND HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE
2 shared
WATSON LABS
Shared indications:
HypertensionMyocardial Infarction
MAXZIDE
HYDROCHLOROTHIAZIDE
2 shared
Aurobindo Pharma
Shared indications:
HypertensionMyocardial Infarction
MAXZIDE-25
HYDROCHLOROTHIAZIDE
2 shared
Aurobindo Pharma
Shared indications:
HypertensionMyocardial Infarction
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

EDARBYCLOR FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such a...

โš ๏ธ BOXED WARNING

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Edarbyclor as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Pre...

EDARBYCLOR Patents & Exclusivity

Latest Patent: Jun 2031

Patents (12 active)

US9387249 Expires Jul 1, 2031
US9169238 Expires Feb 4, 2030
US9066936 Expires Mar 26, 2028
+ 2 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.